Amplius Wealth Advisors LLC Sells 32,854 Shares of Pfizer Inc. $PFE

Amplius Wealth Advisors LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 75.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,438 shares of the biopharmaceutical company’s stock after selling 32,854 shares during the quarter. Amplius Wealth Advisors LLC’s holdings in Pfizer were worth $260,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PFE. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer during the third quarter worth approximately $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer in the 2nd quarter valued at $30,000. Darwin Wealth Management LLC bought a new stake in Pfizer during the 2nd quarter valued at $32,000. True Wealth Design LLC increased its stake in Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares in the last quarter. Finally, Sagard Holdings Management Inc. acquired a new position in Pfizer during the second quarter worth $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent research reports. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Wednesday, February 4th. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Guggenheim lifted their price target on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $28.19.

Pfizer Trading Up 0.8%

Shares of PFE stock opened at $26.98 on Wednesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The company has a market capitalization of $153.39 billion, a price-to-earnings ratio of 19.83 and a beta of 0.47. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.94. The company has a 50-day simple moving average of $26.75 and a two-hundred day simple moving average of $25.64.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter last year, the firm earned $0.63 EPS. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst upgrade/price-target bump: Guggenheim raised its Pfizer price target to $36 and holds a Buy rating, backing upside tied to key pipeline readouts and boosting sentiment among growth/pipeline-focused investors. Guggenheim price target report
• Positive Sentiment: Pipeline upside — prostate cancer and oncology momentum: Several analysts highlight potential high-value outcomes from an ongoing prostate-cancer trial and broader oncology progress, suggesting binary upside that could re-rate the stock if positive. Analyst bullish case on prostate cancer trial
• Neutral Sentiment: Management investor access — Q1 webcast scheduled for May 5: Pfizer invited the public to view a May 5 analyst call tied to its First Quarter 2026 Performance Report; that scheduled update creates a clear near-term catalyst for guidance or pipeline commentary. May 5 webcast invitation
• Neutral Sentiment: Management highlights oncology milestones: CFO Dave Denton discussed recent oncology progress on NYSE Live, reinforcing management’s message that non-COVID franchises and oncology are growth pillars. This supports a constructive narrative but is not immediately revenue-producing. CFO oncology interview
• Negative Sentiment: Lyme vaccine trial—strong efficacy but missed primary endpoint: Pfizer and partner Valneva reported >70% efficacy, yet the trial missed its pre-specified primary endpoint because fewer cases occurred than expected. That creates regulatory and execution uncertainty; Valneva’s shares plunged, underscoring market concern about read-across risk. Pfizer will pursue regulatory filings, but approval risk and timing remain uncertain. Lyme vaccine efficacy and trial miss

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.